北京商报讯（记者 胡永新）2月6日，北京商报记者了解到，近期，中央网信办会同国家医保局深入整 治涉医药集中带量采购的网上虚假不实信息，依法依约处置一批污名集采、制造焦虑、误导公众的账 号。根据通报的典型案例，微博账号"成都XXX"，抖音账号"琼波XX""亮晶晶的XX"等，歪曲国家政 策，编造"进口药集体退出中国"等不实信息，煽动网民对原研药与仿制药的对立情绪，其中部分账号旨 在制造公众用药焦虑，引导公众购买相关保健品、高端医疗保险，或诱导公众到特定的互联网平台购 药。涉及的账号已被依法依约采取处置措施。 ...

围绕这一目标，浙江将推动经济高质量发展、实施就业优先战略作为两大核心抓手，以产业创新筑牢物质基础，以就业提 质实现发展成果普惠，同时深度融入长三角一体化发展，走出具有浙江特色的共同富裕之路。 "芯模联动"领航 近日，《浙江省"十五五"高质量发展建设共同富裕示范区规划（征求意见稿）》（下称《征求意见稿》）公布，明确到 2030年基本建成高质量发展高品质生活先行区，人均地区生产总值和城乡居民收入接近发达经济体水平。 在夯实共同富裕物质基础上，浙江将科技创新与产业升级深度融合，既以人工智能为核心打造创新高地，又通过先进制造 业集群培育优化现代化产业体系，同时推动长三角产业协同发展。 打造人工智能创新发展高地是浙江的重要战略布局，而"芯模联动"则成为破题关键。早在2025年5月，浙江便出台支持人工 智能创新发展的专项措施，将"芯模联动"列为重点任务。 《征求意见稿》进一步提出，统筹全省算力资源构建多层次算力服务体系，实施"芯模联动"行动，打造世界一流"基础+垂 类"模型群，并营造最优开源开放生态。 作为浙江AI发展的核心引擎，杭州正以"芯模联动"为抓手冲击"AI第一城"，而浙江的算力布局侧重开源共享，并非封闭发 展， ...

Group 1 - The core point of the article is that Yiming Pharmaceutical (002826.SZ) has stated on its investor interaction platform that the company does not have any original research drug products [1]

Group 1 - The core point of the article is that Yiming Pharmaceutical (002826.SZ) has stated on its investor interaction platform that the company does not have any original research drug products [1]

Group 1 - The "2025 Responsibility Shine Qilu" annual event recognized Qilu Pharmaceutical as a "Responsible Enterprise" for its outstanding performance in drug research and development, public health support, and industry responsibility [1] - The event was attended by leaders from the Shandong Provincial Health Commission, Shandong Digital Culture Group, and representatives from nearly a hundred medical institutions, highlighting the importance of recognizing contributions to the health sector in Shandong [1] - The awards were based on public recommendations, sentiment analysis, big data evaluation, and reader feedback, aiming to set benchmarks for industry responsibility [1] Group 2 - Qilu Pharmaceutical focuses on major diseases such as tumors, infections, and autoimmune diseases, increasing R&D investment and establishing a global innovation platform to ensure high-quality drug supply [2] - The company has implemented a comprehensive quality control system and adheres to international standards to ensure the safety and reliability of its products [2] - Qilu Pharmaceutical actively engages in social responsibility through initiatives like "Healthy China, Qilu Together," providing free health screenings and educational outreach in underserved areas [2] Group 3 - In 2025, Qilu Pharmaceutical achieved significant breakthroughs, including multiple innovative drugs entering critical clinical trial phases and establishing a leading smart pharmaceutical production base [3] - The company has enhanced production efficiency and quality control through digital and intelligent transformations, ensuring stable drug supply [3] - Qilu Pharmaceutical aims to continue its commitment to pharmaceutical innovation and public health services, responding to national health initiatives and driving high-quality development in the Chinese pharmaceutical industry [3]

Core Viewpoint - Suzhou Naxin Microelectronics Co., Ltd. has officially listed on the Hong Kong Stock Exchange, marking the first company from Suzhou to achieve dual listing in both A-share and H-share markets, highlighting the growing trend of "A+H" listings in the Yangtze River Delta region [1][2]. Group 1: Company Overview - Naxin Micro is a leading high-performance analog chip company focusing on sensors, signal chains, and power management, providing reliable semiconductor products and solutions for automotive, industrial, information communication, and consumer electronics sectors [4]. - The company raised a total of 5.8 billion yuan during its initial public offering on the Shanghai Stock Exchange in April 2022 [2]. Group 2: Industry Trends - The trend of A-share companies seeking dual listings in Hong Kong has become a strategic choice for expanding investor bases and financing channels, enhancing international visibility and facilitating cross-border capital operations [1][2]. - Since 2025, there has been a surge in A-share companies from the Yangtze River Delta pursuing dual listings, with strategic emerging industries becoming the main focus [2][3]. - Other companies in the region, such as Heng Rui Pharmaceutical and Junsheng Electronics, have also successfully listed on the Hong Kong Stock Exchange, indicating a broader trend of leveraging dual capital platforms for global expansion and technological upgrades [2][3]. Group 3: Future Outlook - Naxin Micro aims to leverage its Hong Kong listing as a milestone for global narrative, increasing investment in foundational technologies, expanding product offerings, and enhancing overseas sales and market systems [4]. - The current wave of "A+H" listings reflects the strategic pursuit of diversified financing channels, higher international visibility, and global resource allocation capabilities by companies in the Yangtze River Delta [4].

Core Viewpoint - Both JD Health (06618) and Alibaba Health (00241) reported strong performance in Q3 this year, but the fourth quarter guidance is considered conservative due to the base effect of the trade-in policy. The outlook for drug sales growth and profit margin expansion for next year remains positive [1] Group 1: Company Performance - JD Health and Alibaba Health are expected to achieve double-digit revenue growth next year, with JD Health anticipated to grow at a faster rate [1] - JD Health's target price is set at HKD 71, while Alibaba Health's target price has been lowered from HKD 6.5 to HKD 6 to reflect a slowdown in third-party product transaction volume and revenue growth expectations [1] Group 2: Market Trends - The trend of original drug sales shifting from hospital channels to external channels, along with pharmaceutical marketing budgets moving online, is expected to continue for several years [1] - Both companies are projected to have a revenue year-on-year growth rate of around 15% in the next quarter, supported by ongoing growth in original drug sales [1] Group 3: Long-term Projections - JD Health is expected to achieve nearly 20% year-on-year revenue growth in the fiscal year 2026, while Alibaba Health is projected to achieve low teens year-on-year revenue growth in the fiscal year 2027 [1] - Due to the high base effect from the trade-in policy, medical device sales may slow down, and Alibaba Health may face greater pressure in nutrition products, third-party GMV, and revenue [1] - The long-term adjusted net profit margin for both companies is approximately 13% [1]

Core Viewpoint - Both JD Health (06618) and Alibaba Health (00241) reported strong performance in Q3 this year, but due to the base effect of the trade-in policy, their Q4 performance guidance is considered conservative. However, there is a positive outlook for drug sales growth and profit margin expansion in the coming year [5]. Group 1: Company Performance - JD Health and Alibaba Health are expected to achieve double-digit revenue growth next year, with JD Health anticipated to grow at a faster rate [5]. - JD Health's target price is set at HKD 71, while Alibaba Health's target price has been lowered from HKD 6.5 to HKD 6, reflecting a slowdown in third-party goods transaction volume and revenue growth expectations [5]. - Both companies maintain an "outperform" rating [5]. Group 2: Market Trends - The trend of original drug sales shifting from hospital channels to external channels, along with pharmaceutical marketing budgets moving online, is expected to continue for several years [5]. - Revenue growth rates for both companies in the next quarter are projected to be around 15% year-on-year [5]. Group 3: Future Projections - JD Health is expected to achieve nearly 20% year-on-year revenue growth in the fiscal year 2026, while Alibaba Health is projected to achieve low teens year-on-year revenue growth in the fiscal year 2027 [5]. - Due to the high base effect of the trade-in policy, sales of medical devices may slow down, and Alibaba Health may face greater pressure in nutrition products, third-party goods transaction volume (GMV), and revenue [5]. - The long-term adjusted net profit margin for both companies is approximately 13% [5].

Summary of Conference Call Notes on Alibaba Health Company Overview - **Company**: Alibaba Health (0241.HK) - **Current Rating**: Neutral - **Target Price**: HKD 6.50 by December 2026 Key Points and Arguments Revenue Growth - Alibaba Health achieved a **17% revenue growth** in the first half of fiscal year 2026, driven by: 1. Strong growth in original research drugs due to structural changes in the Chinese pharmaceutical market 2. Synergistic effects from Taobao's flash sales [1][7][12] Future Outlook - The growth from original research drugs is expected to continue driving platform sales in the foreseeable future. However, the sustainability of the incremental contributions from flash sales remains uncertain [1][12] - Investors are advised to focus on: 1. Fluctuations in Taobao flash sales subsidy levels 2. Potential investment scale 3. User retention after subsidies return to normal levels [1][12] Financial Adjustments - Adjusted earnings per share (EPS) for FY26E increased from **0.15 to 0.16**, reflecting an **8.7%** increase [2][10] - Revenue estimates for FY26E were raised from **34,307 million to 35,293 million**, a **2.9%** increase [2][10] - For FY27E, revenue estimates were adjusted from **36,878 million to 37,893 million**, a **2.8%** increase [2][10] Performance Metrics - The adjusted net profit margin improved to **8.1%**, up **1.3 percentage points** [5] - The company expects a **15%** revenue growth for FY26, with a **14%** growth in the second half, indicating a slowdown compared to the first half [5] Flash Sales Impact - Taobao's flash sales have significantly increased user traffic and transaction frequency on Alibaba Health's platform, particularly in contact lenses, with search volume growth exceeding **10%** [5] - Increased traffic has boosted advertising revenue as merchants allocate more marketing budgets to capture demand [5] Risks and Considerations - Key risks affecting the rating and target price include: 1. Potential regression or slow execution of policy support 2. Slower-than-expected online penetration for purchasing medications and consultations 3. Intensified competition from other e-pharmacy platforms and online medical service providers [14] - Upside risks include: 1. Relaxation of internet regulations 2. Introduction of favorable policies for the online healthcare industry 3. Significant improvement in conversion rates of existing users on the Alibaba platform [14] Additional Important Information - The stock has shown a **64.2%** increase year-to-date, but a **10.8%** decline over the past 12 months [6] - The company has a market capitalization of **11,318 million USD** and a free float of **41.6%** [6] - The target price is based on a **2.5x** enterprise value/revenue multiple for FY26, which is within the range of **2.1-5.5x** for listed online healthcare platforms [12][13] This summary encapsulates the essential insights from the conference call regarding Alibaba Health's performance, outlook, and the factors influencing its market position.

Macro and Strategy - The report highlights a significant shift in China's economic growth engine from the secondary industry to the more promising tertiary industry (services) in 2025, with a focus on expanding domestic consumption as the main driver of demand [8][9] - The concept of "anti-involution" is introduced, emphasizing the need to control supply while expanding demand, particularly in the physical product sector, which is crucial for optimizing supply and enhancing new productive forces [8][9] - The interdependence between the service and manufacturing sectors is emphasized, where manufacturing acts as an incubator for productive services, and the growth of services creates a substantial market for manufactured goods [8][10] Industry and Company Insights - The public and environmental protection industry report indicates that the Ministry of Finance has preemptively allocated the first batch of ecological and environmental protection funds for 2026, and there is an analysis of the electricity trading plan in Sichuan for 2026 [3] - The electronic industry report discusses the resonance between AI computing power and terminal innovation, suggesting that PCB (Printed Circuit Board) technology is reshaping high-density connectivity [3] - The agricultural industry report notes a steady increase in beef prices, indicating a positive outlook for the meat and dairy cycle [3] - The financial engineering report highlights the performance of various investment strategies, with a focus on small-cap growth stocks outperforming [3][20] Market Trends - The report provides an overview of major market indices, noting that the Shanghai Composite Index closed at 3888.59 points, with a slight increase of 0.34% [2] - The bond market experienced a significant correction, with short-term bonds remaining stable due to central bank liquidity support, while long-term bonds faced fluctuations due to policy concerns [12][18] - The REITs market is expanding, with the report indicating that the China Securities Regulatory Commission has initiated a pilot program for commercial real estate REITs, which is a key step in diversifying the REITs market [20][24]